CD8A and neoplasm: Eight days after tumor injection the blood profile indicated that the majority of cells obtained had a CD62Llow effector T cell (TE) phenotype (Figure 5C,D) and a substantial expansion of OVA-specific CD8+ T cells was evident (Figure 5A,B).